[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370289-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370289-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lsd1-is-a-targetable-vulnerability-in-gastric-cancer-harboring-tp53-frameshift-mutations","LSD1 is a targetable vulnerability in gastric cancer harboring TP53 frameshift mutations","","TP53 frameshift mutations in gastric cancer remain poorly characterized, and no targeted therapy has been established for affected patients. This study evaluates histone demethylase inhibition as a therapeutic strategy for TP53-mutant subtypes, focusing on frameshift events. Across gastric cancer cell lines, the LSD1 inhibitor GSK690 selectively suppresses TP53 frameshift mutations lacking p53 nuclear localization sequence, causing G1/S arrest via the LSD1-CCNA2 axis and disrupting p53 transcriptional repression. Results indicate LSD1-CCNA2 is aberrantly activated in this subtype, supporting GSK690 as a precise option.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lsd1-is-a-targetable-vulnerability-in-gastric-cancer-harboring-tp53-frameshift-mutations/370289/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lsd1-is-a-targetable-vulnerability-in-gastric-cancer-harboring-tp53-frameshift-mutations/370289.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are TP53 frameshift mutations in gastric cancer clinically important?","Question",{"text":63,"@type":64},"They are linked to aggressive progression and chemoresistance, and frameshift mutations represent a major TP53 mutation type. However, their consequences in gastric cancer and targeted therapeutic options were not well established.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the study identify as the key therapeutic vulnerability?",{"text":68,"@type":64},"The histone demethylase inhibitor GSK690, targeting LSD1, selectively inhibits gastric cancer cells harboring TP53 frameshift mutations without p53 nuclear localization sequence (TP53 Frameshift NLS).",{"name":70,"@type":61,"acceptedAnswer":71},"How does GSK690 inhibit tumor growth in this TP53 frameshift NLS subtype?",{"text":72,"@type":64},"GSK690 induces G1/S cell cycle arrest via the LSD1-CCNA2 axis and confirms transcriptional repression disruption of p53 leading to LSD1 upregulation. This suppresses malignant proliferation in vitro and in vivo.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370289,1790334942,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Wang et al. Clinical Epigenetics (2025) 17:26 [https://doi.org/10.1186/s13148-025-01829-9](https://doi.org/10.1186/s13148-025-01829-9)  \nClinical Epigenetics  \n RESEARCH Open Access  \nLSD1 is a targetable vulnerability in gastric cancer harboring TP53 frameshift mutations  \nSuzeng Wang1,2,3, Chunyu Yang2,3, Junhui Tang2,3, Kaiqing Wang1,2,3, Hao Cheng1,2,3, Surui Yao2,3, Zhaohui Huang2,3* and Bojian Fei 1,3*  \nAbstract  \nBackground TP53 mutations are linked to aggressive progression and chemoresistance in gastric cancer (GC) . Frameshift mutation is the second most common mutation type of TP53 . However, the consequences of this mutation type in GC were not well understood, and targeted therapies for cancer patients harboring frameshift mutations were also not established. Histone methylation significantly influences tumorigenesis inTP53-mutated cancers, and related inhibitors are emerging as specific therapeutic strategies.  \nMethods and results By treating GC cell lines harboring various TP53 mutation types with a library of histone demethylase inhibitors, we identified that GSK690, a reversible inhibitor of lysine-specific demethylase 1 (LSD1), selectively inhibits GC cells harboring TP53 frameshift mutations without nuclear localization sequence (NLS) (termed TP53 Frameshift NLS), which accounts for 89% TP53 frameshift mutations in GC patients. GSK690 showed significant specific inhibition in vitro and in vivo against this subtype by inducing G1/S cell cycle arrest via the LSD1-CCNA2 axis. Importantly, dual-luciferase assays and ChIP-qPCR confirmed that the loss of transcriptional repression activities of p53 in drives LSD1 upregulation inTP53 Frameshift NLS cancer cells.  \nConclusions In summary, our results indicate that the nuclear localization deficiency of p53 accounts for increased expression of LSD1 inTP53 Frameshift NLS GCs. GSK690 inhibits cell cycle progression and tumor growth by suppressing aberrantly activated LSD1-CCNA2 signaling in this GC subtype, counteracting malignant proliferation and thereby providing a precise therapeutic strategy for GC patients with TP53 Frameshift NLS.  \nKeywords Gastric cancer, Histone demethylase, TP53, LSD1, Frameshift mutations  \n*Correspondence:  \nZhaohui Huang [zhaohuihuang@jiangnan.edu.cn](zhaohuihuang@jiangnan.edu.cn)[ ](zhaohuihuang@jiangnan.edu.cn)Bojian Fei  \n[wx4yfbj@163.com](wx4yfbj@163.com)  \n1 Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangnan University, Wuxi 214062, Jiangsu, China  \n2 Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi 214062, Jiangsu, China  \n3 Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, Jiangsu, China  \nIntroduction  \nGastric cancer (GC) is a global health concern, with the fifth incidence and mortality rates worldwide [1]. TP53 mutations are one of the most common genetic alterations in GC [2]. Unfortunately, GCs harboring TP53 mutations often exhibit chemoresistance, resulting in limited benefits from traditional chemotherapy for these patients [3, 4]. Therefore, there is an urgent need to identify potential targets and develop effective therapies for TP53 mutant GCs.  \nMultiple mutation types in TP53, including missense mutations, frameshift mutations, deletion, and nonsense mutations, have been reported in human cancers, including GC. Among these, frameshift mutation  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this","cbCaivw29tp5EiK2","https://ap.wps.com/l/cbCaivw29tp5EiK2","pdf",14809181,14,"English","# Abstract\n## Background\n## Methods and results\n## Conclusions\n# Introduction\n## TP53 mutations in gastric cancer\n## Frameshift NLS and therapeutic gap","[{\"question\":\"Why are TP53 frameshift mutations in gastric cancer clinically important?\",\"answer\":\"They are linked to aggressive progression and chemoresistance, and frameshift mutations represent a major TP53 mutation type. However, their consequences in gastric cancer and targeted therapeutic options were not well established.\"},{\"question\":\"What did the study identify as the key therapeutic vulnerability?\",\"answer\":\"The histone demethylase inhibitor GSK690, targeting LSD1, selectively inhibits gastric cancer cells harboring TP53 frameshift mutations without p53 nuclear localization sequence (TP53 Frameshift NLS).\"},{\"question\":\"How does GSK690 inhibit tumor growth in this TP53 frameshift NLS subtype?\",\"answer\":\"GSK690 induces G1/S cell cycle arrest via the LSD1-CCNA2 axis and confirms transcriptional repression disruption of p53 leading to LSD1 upregulation. This suppresses malignant proliferation in vitro and in vivo.\"}]","LSD1 is a targetable vulnerability in gastric cancer harboring TP53 frameshift mutations | PDF",1790187798,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77b9165b0d9f9037b4196f36254ec613.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b88ad2aebf61c33add248b9226d9be8.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8aa6a0f7df338116d47fc3c0bfdda318.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac01d378a5ef5de4c9b77a913240ac10.webp",980,1301]